相关实验视频

Updated: Jan 12, 2026

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

一个多中心倾向分数对同源对流体积 (HCV) 的匹配研究:透析剂量的新综合参数,提高生存率

Jorge Quinchuela¹, Gabriela Tamayo², Natalia Benavides³

¹Department of Nephrology, DaVita Ecuador, Unidad Dialcentro, Quito, ECU.

|November 7, 2025

概括

同类对流体积 (HCV) 是一种结合透析参数的新型指标. 较高的HCV,表明更高的透析剂量,与血液透析和血液过患者的显著改善的患者存活率有关.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
临床医学临床医学
患者的治疗结果.

背景情况:

血液过 (HDF) 的有效性通常是通过对流量来评估的,忽视了Kt/V和体外血流 (Qb).
这种监督限制了对透析充分性和患者存活率的全面理解.
为了整合这些因素,提出了一种新的度量,即同类对流体积 (HCV).

研究的目的:

引入和验证同源的对流体积 (HCV) 作为透析剂量的综合衡量标准.
为了比较血液透析和使用HCV的HDF患者之间的死亡率.
为了测试这样的假设,即较高的HCV与较低的患者死亡率相关.

主要方法:

一项涉及14家达维塔-厄瓜多尔诊所的观察性研究包括接受常规血液透析或HDF的患者.
同源的对流体积 (HCV) 计算为:对流体积 * Kt/V * Qb (升/分钟).
根据HCV水平 (0-9.9L, 10-17.9L, ≥18L) 分组患者,并使用倾向性得分匹配,ANOVA和卡普兰-梅尔生存分析进行分析.

主要成果:

倾向性得分匹配创建了可比较的组 (N=2537,213,476),以年龄,并发症,性别和糖尿病为平衡.
两组之间没有发现体重,BMI或并发症的显著差异.
生存时间显著不同:A组 (最低的HCV) 46.9个月,B组 (中等的HCV) 57.8个月,C组 (最高的HCV) 61.9个月 (P<0.001).

结论:

同源的对流体积 (HCV) 提供了对全透析剂量的全面评估,整合了小溶液清除率 (Kt/V),中溶液清除率 (对流) 和血液流量 (Qb).
透析剂量的增加,以更高的HCV来衡量,与患者生存率的提高直接相关.
患者在最高的HCV组 (≥18L) 证明了最长的存活时间,强调了优化透析剂量的重要性.

关键词:

血液过血液过血液过血液透析是血液透析的方法之一.同类的对流体体积.死亡率死亡率倾向得分匹配 (psm) 的方法

更多相关视频

An R-Based Landscape Validation of a Competing Risk Model

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

相关概念视频

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.

Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance

Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance

In healthy individuals, serum creatinine levels remain stable due to a balance between its constant production—primarily from muscle metabolism—and renal excretion. Creatinine is freely filtered by the glomeruli, making it a valuable marker for estimating renal function. When the glomerular filtration rate (GFR) decreases, the kidneys can only eliminate less creatinine, causing serum levels to rise.Serum creatinine concentration is widely used to estimate creatinine clearance...

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...

Renal Failure: Dose Adjustments

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...